Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications

Multiple Sclerosis Clinical Trial

— OUCH  

Official title:

Pilot Study of Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (OUCH)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01834586
• Other study ID #: TRB 2012
• Status: Completed
• Phase: Phase 4
• First received: April 2, 2013
• Last updated: March 14, 2018
• Start date: March 2013
• Est. completion date: March 2015

Study information

• Verified date: March 2018
• Source: Brown, Theodore R., M.D., MPH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see if applying an anesthetic topical adhesive, Synera®, will reduce the injection pain. Relieving injection site pain may improve the tolerability of Multiple Sclerosis medications.

Study Hypothesis: Pre-medication with Synera will have a significant effect on pain ratings as measured by the visual analog scale and Local injection site reaction scale.

Description:

Open-label prospective study of Synera to reduce injection pain in 30 patients with relapsing forms of Multiple Sclerosis taking interferon beta or glatiramer acetate. The duration will be 3-6 weeks (1-2 weeks of baseline observation followed by 2-4 weeks of on-drug observation), depending on which Multiple Sclerosis drug product is being studied. The study will include down-titration from 60 to 30 minutes of application to assess for any difference in responses. We define one primary outcome measure,"pain upon injection" by visual analog scale (VAS). Secondary measures will include 24-hour ratings of pain by VAS and 24-hour local injection site reaction (LISR) scale score.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed diagnosis of Multiple Sclerosis based on McDonald or Poser criteria (no sub-type restrictions)

• Aged >18

• Regular use of one of the follow Multiple Sclerosis medication treatments: interferon beta subcutaneous (15 subjects, Betaseron, Extavia or Rebif), or glatiramer acetate subcutaneous (15 subjects, Copaxone).

• No change in disease modifying therapy in 60 days.

• Mean score of =1.0 on Local Injection Site Reaction scale and Mean Pain Upon Injection score =4.0 during baseline period.

• At least 4 valid diary entries over screening period.

• No Multiple Sclerosis exacerbation for 60 days prior to screening.

• Written informed consent

Exclusion Criteria:

• Females who are breast-feeding, pregnant or have potential to become pregnant during the course of the study (fertile and unwilling/unable to use effective contraceptive measures).

• Cognitive deficits that would interfere with the subject's ability to give informed consent or perform study testing.

• Concurrent application of any topical medication to treat injection site reactions from screening through final visit.

• History of allergy to lidocaine, tetracaine or PABA (para-amino benzoic acid) containing products.

• Patients receiving class 1 antiarrhythmic agents (i.e. tocainide, mexiletine)

• Any other serious and/or unstable medical condition

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• Anesthetic Topical Adhesive Synera
For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks. For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week

Locations

Country	Name	City	State
United States	MS Center at Evergreen Health	Kirkland	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Brown, Theodore R., M.D., MPH

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain Rating	Primary Outcome Measure; •Change from baseline in rating of pain upon injection, recorded immediately post-injection on a 0-10 Visual Analog Scale (VAS, 10 = worst pain, 0 = no pain)Pain upon injection, recorded immediately post-injection on a 0-10 Visual Analog scale (VAS, 10 = worst pain, 0 = no pain).	baseline and two weeks of treatment
Secondary	Average Pain Rating	Average Pain Rating over 24-hours, defined as the average injection-site pain over 24-hours on a 0-10 VAS (0 = no pain, 10 = worst pain).	baseline and two weeks